India's Shilpa Medicare gains after European regulatory nod for anti-blood-clot drug
23/09/2025 05:27
** Shares of Shilpa Medicare SHME.NS rise 3.2% to 845 rupees, their biggest intraday-pct gain in over 5 weeks ** Drug maker gets initial clearance from European drug regulator recommending final approval to sell Rivaroxaban Orodispersible Films, used to treat blood clots, heart attack, stroke in adults ** Europe market for oral Rivaroxaban formulations seen at about $2.5 billion - SHME ** Over 135,000 shares traded, over twice the 30-day avg ** Stock up 3.6% YTD (Reporting by Aleef Jahan) ((aleefjahan.cs@thomsonreuters.com))
Recent news on Shilpa Medicare
See all newsBrief: Shilpa Medicare Q2 Consol Net Profit INR 791.8 Million
Brief: Shilpa Medicare Says USFDA Conducts Surveillance Inspection At Shilpa Medicare Unit
Brief: Shilpa Medicare Receives Final SEC Approval For Oeris Marketing Authorization
India's Shilpa Medicare gains on approval for OERIS
Brief: Shilpa Medicare Initiates Voluntary Recall Of 27,923 Pemetrexed Injection Vials In Us On July 29, 2026